Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Editorial

Exploring New Vista for Alzheimer's Disease Drug Targets (Part II)

Author(s): Andrew A. Bolinger and Jia Zhou

Volume 23, Issue 13, 2023

Published on: 26 June, 2023

Page: [1211 - 1213] Pages: 3

DOI: 10.2174/156802662313230626121232

Price: $65

conference banner
[1]
Grobler, C.; van Tongeren, M.; Gettemans, J.; Kell, D.B.; Pretorius, E. Alzheimer’s Disease: A Systems View Provides a Unifying Explanation of Its Development. J. Alzheimers Dis., 2023, 91(1), 43-70.
[2]
Gustavsson, A.; Norton, N.; Fast, T.; Frolich, L.; Georges, J.; Holzapfel, D.; Kirabali, T.; Krolak-Salmon, P.; Rossini, P.M.; Ferretti, M.T.; Lanman, L.; Chadha, A.S.; van der Flier, W.M. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement., 2023, 19(2), 658-670.
[3]
Bagga, S.; Kumar, M. Current Status of Alzheimer’s Disease and Pathological Mechanisms Investigating the Therapeutic Molecular Targets. Curr. Mol. Med., 2023, 23(6), 492-508.
[4]
Kuo, Y.C.; Rajesh, R. Challenges in the treatment of Alzheimer’s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors. Expert Rev. Neurother., 2019, 19(7), 623-652.
[5]
Vaz, M.; Silvestre, S. Alzheimer’s disease: Recent treatment strategies. Eur. J. Pharmacol., 2020, 887, 173554.
[6]
Marsool, M.D.M.; Prajjwal, P.; Reddy, Y.B.; Marsool, A.D.M.; Lam, J.R.; Nandwana, V. Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Dis. Mon., 2023, 69(5), 101547.
[7]
Shi, M.; Chu, F.; Zhu, F.; Zhu, J. Impact of Anti-amyloid-beta Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Front. Aging Neurosci., 2022, 14, 870517.
[8]
Saeedi, M.; Mehranfar, F. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer’s Disease. Recent Pat. Biotechnol., 2022, 16(2), 102-121.
[9]
Kuns, B.; Rosani, A.; Varghese, D. Memantine. In StatPearls Treasure Island (FL) ineligible companies. Disclosure: Alan Rosani declares no relevant financial relationships with ineligible companies. Disclosure: Dona Varghese declares no relevant financial relationships with ineligible companies., 2023.
[10]
Pluta, R.; Ulamek-Koziol, M. Tau Protein-Targeted Therapies in Alzheimer's Disease: Current State and Future Perspectives. In: Alzheimer's Disease: Drug Discovery; Huang, X, Ed.; Brisbane (AU), 2020.
[11]
Haage, V.; De Jager, P.L. Neuroimmune contributions to Alzheimer’s disease: a focus on human data. Mol. Psychiatry, 2022, 27(8), 3164-3181.
[12]
Klyucherev, T.O.; Olszewski, P.; Shalimova, A.A.; Chubarev, V.N.; Tarasov, V.V.; Attwood, M.M.; Syvanen, S.; Schioth, H.B. Advances in the development of new biomarkers for Alzheimer’s disease. Transl. Neurodegener., 2022, 11(1), 25.
[13]
Aramadaka, S.; Mannam, R.; Sankara Narayanan, R.; Bansal, A.; Yanamaladoddi, V.R.; Sarvepalli, S.S.; Vemula, S.L. Neuroimaging in Alzheimer’s Disease for Early Diagnosis: A Comprehensive Review. Cureus, 2023, 15(5), e38544.
[14]
Kumar, A.; Nehra, B.; Singh, D.; Kumar, D.; Chawla, P.A. Recent Advances in the Development of Nitrogen-containing Heterocyclic Anti-Alzheimer’s Agents. Curr. Top. Med. Chem., 2023, 23(13), 1277-1306.
[15]
Sharma, A.; Piplani, P. Acridine: A Scaffold for the Development of Drugs for Alzheimer’s Disease. Curr. Top. Med. Chem., 2023, 23(13), 1260-1276.
[16]
Arbones, M.L.; Thomazeau, A.; Nakano-Kobayashi, A.; Hagiwara, M.; Delabar, J.M. DYRK1A and cognition: A lifelong relationship. Pharmacol. Ther., 2019, 194, 199-221.
[17]
Yang, S.; Shao, H.; Chen, X.; Liu, Q.; Huang, S.; Huang, Y. Plants of the Genus Mahonia as a Potential Traditional Chinese Medicine for the Prevention and Treatment of Alzheimer’s Disease. Curr. Top. Med. Chem., 2023, 23(13), 1214-1220.
[18]
Thakral, S.; Yadav, A.; Singh, V.; Kumar, M.; Kumar, P.; Narang, R.; Sudhakar, K.; Verma, A.; Khalilullah, H.; Jaremko, M.; Emwas, A.H. Alzheimer’s disease: Molecular aspects and treatment opportunities using herbal drugs. Ageing Res. Rev., 2023, 88, 101960.
[19]
Grover, P.; Rohilla, S.; Bhardwaj, M.; Mehta, L.; Malhotra, A. Piperidine Nucleus as a Promising Scaffold for Alzheimer’s Disease: Current Landscape and Future Perspective. Curr. Top. Med. Chem., 2023, 23(13), 1221-1259.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy